Adverse Events for New Cholesterol Drugs Low, But Long-Term Effects Unknown

Side Effects for New Cholesterol Drugs Low, But Long-Term Effects Unknown

Patients taking the newest class of cholesterol-lowering drugs do not experience any more side effects than those on a placebo, though those on a PCSK9 inhibitor may have an increased risk for cataracts.

Researchers conducted a meta-analysis – a study of studies – that included 5,234 patients treated with Praluent (alirocumab), a PCSK9 that is given by injection, for up to 2 years. Side effects were similar in patients taking Praluent compared to those on a placebo, the researchers reported in the Journal of the American College of Cardiology.

Side effects observed included musculoskeletal disorders, neurologic and neurocognitive conditions (including memory impairment), and renal or liver problems. However, analyses indicated an increased incidence of cataracts in patients with low LDL levels. The researchers believe this could be because lowering cholesterol speeds up underlying aging-related changes, contributing to cataracts.

However, Dr. Jennifer Robinson, a professor of epidemiology and medicine at the University of Iowa and the study’s lead author, noted that the long-term effects of PCSK9 treatment are still unknown and statins should remain the preferred therapy to achieve cardiovascular risk reduction.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement